Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbon ion radiotherapy combined with nimotuzumab and gemcitabine for pancreatic cancer
ChiCTR2100049286Phase 2Not yet recruiting
- Sponsor
- Wuwei Tumor Hospital Heavy Ion Center
- Start
- Aug 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab and gemcitabine in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Wuwei Tumor Hospital Heavy Ion Center. Primary endpoint: 1-year overall survival rate. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
nimotuzumabgemcitabine
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2100049286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049286.